Physician profile
Larisa Syrow
NPI 1639364037
$149,615.85
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $21K · 2021: $68K · 2022: $28K · 2023: $3,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,832 · Food and Beverage: $91.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,831.50 |
| Food and Beverage | $91.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $37,055.52 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $30,746.90 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $29,185.28 | 2019-2023 | Ajovy |
| Abbvie INC. | $19,431.58 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $15,837.39 | 2022-2023 | Trudhesa |
| Allergan, INC. | $8,275.09 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $6,698.94 | 2022 | |
| Supernus Pharmaceuticals, INC. | $721.78 | 2019 | |
| Celgene Corporation | $414.22 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $260.82 | 2020-2022 | |
| Sk Life Science, INC. | $225.64 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $146.17 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $86.56 | 2019 | |
| Ucb, INC. | $79.29 | 2020-2021 | |
| Lilly USA, LLC | $67.23 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $52.78 | 2019 | |
| Bausch Health US, LLC | $44.94 | 2019-2020 | |
| Biogen, INC. | $41.76 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $39.47 | 2019 | |
| Vifor Pharma, INC. | $37.42 | 2019-2021 | |
| Eisai INC. | $29.72 | 2021-2022 | |
| Lundbeck LLC | $29.18 | 2019 | |
| Promius Pharma LLC | $28.47 | 2019 | |
| Assertio Therapeutics, INC. | $15.56 | 2019 | |
| Acorda Therapeutics, INC | $14.06 | 2019 | |
| Upsher-Smith Laboratories LLC | $14.01 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $12.74 | 2019 | |
| Neurocrine Biosciences, INC. | $12.08 | 2020 | |
| Alnylam Pharmaceuticals INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larisa Syrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.